Alector Announces Results From AL002 INVOKE-2 Phase 2 Trial In Individuals With Early ...
(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 ...